Company: BLCO
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001860742-25-000023
Chunk: 130

Company: Bausch & Lomb Corp
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 2
Chunk 130
---
 certain enVista IOL products, as previously discussed. This increase included: (i) incremental sales from acquisitions of $15 million, (ii) an increase in volumes of $10 million, (iii) the favorable impact of foreign currencies of $7 million and (iv) an increase in net realized pricing of $1 million.Cash Discounts and Allowances, Chargebacks and Distribution FeesProvisions recorded to reduce gross product sales to net product sales and revenues for the nine months ended September 30, 2025 and 2024 were as follows:Nine Months Ended September 30,20252024(in millions)AmountPct.AmountPct.Gross product sales$6,050 100.0 %$5,459 100.0 %Provisions to reduce gross product sales to net product salesDiscounts and allowances346 5.70 %315 5.80 %Returns53 0.90 %74 1.40 %Rebates1,446 23.80 %1,046 19.10 %Chargebacks451 7.50 %468 8.60 %Distribution fees72 1.20 %57 1.00 %Total provisions2,368 39.10 %1,960 35.90 %Net product sales3,682 60.90 %3,499 64.10 %Other revenues14 12 Revenues$3,696 $3,511 Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 39.1% and 35.9% for the nine months ended September 30, 2025 and 2024, respectively, an increase of 3.2% percentage points, and is primarily attributable to the increase in rebates from our dry eye portfolio, including XIIDRA® and MIEBO®.Operating ExpensesCost of Goods Sold (exclusive of amortization and impairments of intangible assets)Cost of goods sold was $1,513 million and $1,369 million for the nine months ended September 30, 2025 and 2024, respectively, an increase of $144 million, or 11%. The increase was primarily driven by: (i) higher volumes and (ii) higher manufacturing variances, which include an inventory reserve related to the voluntary recall of certain enVista IOL products.Contribution (product sales